Cargando…

Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis

PURPOSE: This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy (NCT) and neoadjuvant immunotherapy combined with chemotherapy (NICT) combined with radical lung cancer resection for the treatment of patients with resectable non-small cell lung cancer (NSCLC). To adjust for c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Junfeng, Hao, Shaoyu, Li, Ying, Liu, Xiaoman, Liu, Zhaoxuan, Zheng, Chunhui, Han, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651418/
https://www.ncbi.nlm.nih.gov/pubmed/38026088
http://dx.doi.org/10.2147/ITT.S437911
_version_ 1785135992517165056
author Zhao, Junfeng
Hao, Shaoyu
Li, Ying
Liu, Xiaoman
Liu, Zhaoxuan
Zheng, Chunhui
Han, Dan
author_facet Zhao, Junfeng
Hao, Shaoyu
Li, Ying
Liu, Xiaoman
Liu, Zhaoxuan
Zheng, Chunhui
Han, Dan
author_sort Zhao, Junfeng
collection PubMed
description PURPOSE: This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy (NCT) and neoadjuvant immunotherapy combined with chemotherapy (NICT) combined with radical lung cancer resection for the treatment of patients with resectable non-small cell lung cancer (NSCLC). To adjust for confounding factors, we innovatively adopted two matching methods: propensity score (PS) and inverse probability of treatment weighting (IPTW). PATIENTS AND METHODS: We conducted a retrospective analysis of the clinicopathological features and prognosis of patients with resectable NSCLC treated with NCT or NICT combined with radical lung cancer resection using propensity score matching (PSM) at a ratio of 1:1 and IPTW to balance potential bias. RESULTS: After PSM, 116 pairs of patients who had undergone NCT or NICT were selected for the final analysis. The pathological complete remission (pCR) and major pathological remission (MPR) rates were significantly better in the NICT group than in the NCT group (pCR rate of 44.8% vs 2.6%, P< 0.001; MPR rate of 66.4% vs 20.7%, P< 0.001). No significant difference was seen between the NICT and NCT groups in terms of postoperative complications (12.1% vs 9.5%, P=0.182). Patients in the NICT group had significantly better disease-free survival (DFS) and overall survival(OS) than those in the NCT group ([3-year DFS: 75.2% vs 43.3%, P< 0.001] and [3-year OS: 91.5% vs 58.0%, P< 0.001]). Among all patients, those with postoperative pathology of pCR had better DFS (P< 0.001) and OS (P= 0.009). Patients with postoperative pathology of MPR had better DFS (P< 0.001) and OS (P< 0.001). The IPTW method yielded similar pathologic and prognostic results. CONCLUSION: Patients with resectable NSCLC treated with NICT had better pathological responses and prognosis, than those treated with NCT, and the safety profiles of NICT and NCT were similar.
format Online
Article
Text
id pubmed-10651418
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106514182023-11-11 Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis Zhao, Junfeng Hao, Shaoyu Li, Ying Liu, Xiaoman Liu, Zhaoxuan Zheng, Chunhui Han, Dan Immunotargets Ther Original Research PURPOSE: This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy (NCT) and neoadjuvant immunotherapy combined with chemotherapy (NICT) combined with radical lung cancer resection for the treatment of patients with resectable non-small cell lung cancer (NSCLC). To adjust for confounding factors, we innovatively adopted two matching methods: propensity score (PS) and inverse probability of treatment weighting (IPTW). PATIENTS AND METHODS: We conducted a retrospective analysis of the clinicopathological features and prognosis of patients with resectable NSCLC treated with NCT or NICT combined with radical lung cancer resection using propensity score matching (PSM) at a ratio of 1:1 and IPTW to balance potential bias. RESULTS: After PSM, 116 pairs of patients who had undergone NCT or NICT were selected for the final analysis. The pathological complete remission (pCR) and major pathological remission (MPR) rates were significantly better in the NICT group than in the NCT group (pCR rate of 44.8% vs 2.6%, P< 0.001; MPR rate of 66.4% vs 20.7%, P< 0.001). No significant difference was seen between the NICT and NCT groups in terms of postoperative complications (12.1% vs 9.5%, P=0.182). Patients in the NICT group had significantly better disease-free survival (DFS) and overall survival(OS) than those in the NCT group ([3-year DFS: 75.2% vs 43.3%, P< 0.001] and [3-year OS: 91.5% vs 58.0%, P< 0.001]). Among all patients, those with postoperative pathology of pCR had better DFS (P< 0.001) and OS (P= 0.009). Patients with postoperative pathology of MPR had better DFS (P< 0.001) and OS (P< 0.001). The IPTW method yielded similar pathologic and prognostic results. CONCLUSION: Patients with resectable NSCLC treated with NICT had better pathological responses and prognosis, than those treated with NCT, and the safety profiles of NICT and NCT were similar. Dove 2023-11-11 /pmc/articles/PMC10651418/ /pubmed/38026088 http://dx.doi.org/10.2147/ITT.S437911 Text en © 2023 Zhao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhao, Junfeng
Hao, Shaoyu
Li, Ying
Liu, Xiaoman
Liu, Zhaoxuan
Zheng, Chunhui
Han, Dan
Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
title Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
title_full Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
title_fullStr Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
title_full_unstemmed Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
title_short Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
title_sort comparative efficacy and safety of neoadjuvant immunotherapy with chemotherapy versus chemotherapy alone in non-small cell lung cancer: a propensity score and inverse probability treatment weighting analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651418/
https://www.ncbi.nlm.nih.gov/pubmed/38026088
http://dx.doi.org/10.2147/ITT.S437911
work_keys_str_mv AT zhaojunfeng comparativeefficacyandsafetyofneoadjuvantimmunotherapywithchemotherapyversuschemotherapyaloneinnonsmallcelllungcancerapropensityscoreandinverseprobabilitytreatmentweightinganalysis
AT haoshaoyu comparativeefficacyandsafetyofneoadjuvantimmunotherapywithchemotherapyversuschemotherapyaloneinnonsmallcelllungcancerapropensityscoreandinverseprobabilitytreatmentweightinganalysis
AT liying comparativeefficacyandsafetyofneoadjuvantimmunotherapywithchemotherapyversuschemotherapyaloneinnonsmallcelllungcancerapropensityscoreandinverseprobabilitytreatmentweightinganalysis
AT liuxiaoman comparativeefficacyandsafetyofneoadjuvantimmunotherapywithchemotherapyversuschemotherapyaloneinnonsmallcelllungcancerapropensityscoreandinverseprobabilitytreatmentweightinganalysis
AT liuzhaoxuan comparativeefficacyandsafetyofneoadjuvantimmunotherapywithchemotherapyversuschemotherapyaloneinnonsmallcelllungcancerapropensityscoreandinverseprobabilitytreatmentweightinganalysis
AT zhengchunhui comparativeefficacyandsafetyofneoadjuvantimmunotherapywithchemotherapyversuschemotherapyaloneinnonsmallcelllungcancerapropensityscoreandinverseprobabilitytreatmentweightinganalysis
AT handan comparativeefficacyandsafetyofneoadjuvantimmunotherapywithchemotherapyversuschemotherapyaloneinnonsmallcelllungcancerapropensityscoreandinverseprobabilitytreatmentweightinganalysis